Multicentre Investigation of Novel Electrocardiogram Risk Markers in Ventricular Arrhythmia Prediction

This is a prospective open label single blinded multi-centre observational study involving a study group of patients already undergoing implantable cardioverter-defibrillator (ICD)(including Cardiac resynchronisation therapy device (CRT-D)) implant. A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. This EP test will be performed whilst measuring a 12-lead ECG and will be correlated with event rates to establish their effectiveness in predicting arrhythmia risk. The minimum follow up period should be 18 months and maximum of 3 years, which is how long the study is funded for. This study is not randomised as all study patients will be receiving the EP study performed at baseline. A minimum of 440 patients will be recruited to document event data at standard clinical ICD follow up intervals - equating to a maximum of 6 visits. Blinding will be maintained at the core lab were the ECG analysis will be performed by a nominated researcher who will not have details of patient health status.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ventricular Arrythmia Cardiovascular Diseases Death Death, Sudden Death, Sudden, Cardiac Heart Arrest Heart Diseases Ischemic Cardiomyopathy Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hull and East Yorkshire Hospitals NHS Trust, Cottingham, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participant is willing and able to give informed consent for participation in the study
Male or Female, aged 18 years or above
Female participants of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study
Diagnosed with a history of ischaemic cardiomyopathy
Stable, as define as no more than a 100% increase or a 50% decrease, dose of current regular medication as standard for patients at risk of ventricular arrhythmia for at least 4 weeks prior to study entry
Able (in the Investigators opinion) and willing to comply with all study requirements
Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study
Patients must be able to attend follow up at the study site until the study closure
Attending for first time primary prevention ICD (including CRT-D) implantation under THE National Institute for Health and Care Excellence (NICE) criteria
Patients must be able to read and understand English
Stable dose of current regular medication for at least 4 weeks prior to study entry

Exclusion criteria

Within 28 days since acute coronary syndrome/cardiac surgery
Scheduled elective surgery or other procedures requiring general anaesthesia during the study: for example - awaiting coronary revascularisation
Female participants who are pregnant, lactating or planning pregnancy during the course of the study
Contraindications for electrophysiological study

Haemodynamic instability
Severe valvular heart disease as define by British Society of Echocardiography (BSE) guidelines
Symptomatic coronary artery disease (unstable or refractory angina)
Stroke within the last 12 months
Significant renal disease stage i.e. Chronic Kidney Disease stage 5 (requiring renal replacement therapy and / or Estimated glomerular filtration rate (eGFR) <15), or severe liver disease (end stage or presence of cirrhosis)
Participants who have participated in another research study involving an investigational product in the past 12 weeks
Undergone ICD implantation where the right ventricular lead is non-apically positioned e.g. positioned septally
Clinically judged by a cardiologist to require a ventricular tachycardia (VT) therapy zone less than or equal to 200 bpm
Any other significant disease or disorders which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. Specific concerns should be discussed with the Chief / Co - Investigators
Any other interventional research

Treatment and study plan

Primary outcomes

Regional Restitution Instability Index (R2I2), the mean of the standard deviation of the residuals from the mean gradients for each ECG lead across a range of diastolic intervals, will be determined from an EP study carried out at ICD implant.

Time frame: 12 - 36 months
- For each lead of the surface ECG, the QTpeak will be plotted as a function of TpeakQ, and gradients were fitted by using 40ms overlapping least squares linear segments as described previously by Taggart et al. [9]. For each lead, in each 40 ms segment, the difference of the gradient from the mean gradient in that 40 ms segment will be calculated. The mean of the standard deviation of these values will be taken as the R2I2.
- An R2I2 cut-off of 1.03 (no units) will partition the study population into high and low risk groups.
Peak ECG Restitution Slope (PERS), calculated as the peak restitution curve slope taken as a mean across the 12 ECG leads .

Time frame: 12 - 36 months

A PERS cut-off of 1.21 (no units) will partition the study population into high and low risk groups.

Sponsors and collaborators

Lead sponsor

University of Leicester

Other

Registry information

Official study title

Multicentre Investigation of Novel Electrocardiogram Risk Markers in Ventricular Arrhythmia Prediction (MINERVA)

Acronym: MINERVA

Important dates

Study start: 2016
Primary completion: 2022
Study completion: 2022
First posted: Jan 16, 2017
Registry last updated: Jan 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed